Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy.
Li-Tzong Chen
Consultant or Advisory Role - PharmaEngine (U)
Her-Shyong Shiah
No relevant relationships to disclose
Peng-Chan Lin
No relevant relationships to disclose
Jenq-Chang Lee
No relevant relationships to disclose
Wu-Chou Su
No relevant relationships to disclose
Yi-Wen Wang
Employment or Leadership Position - PharmaEngine
Stock Ownership - PharmaEngine
Grace Yeh
Employment or Leadership Position - PharmaEngine
Stock Ownership - PharmaEngine
Jang-Yang Chang
No relevant relationships to disclose